
First-in-Class VS Me-Too Launch Differences and the Role of Content, Hyperpersonalization, and Technology with Frank Dolan, Founder and CEO of ARSENAL
26/10/2022
0:00
39:15
First-in-class medications are often referred to as innovative treatment alternatives. But innovation might scare and push away some HCPs and patients. In this episode of Pharma Launch Secrets, Bozidar is joined by Frank Dolan, Founder, and CEO of ARSENAL
Altri episodi di "Pharma Launch Secrets"
Non perdere nemmeno un episodio di “Pharma Launch Secrets”. Iscriviti all'app gratuita GetPodcast.